Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | NTMT1 | Q9BV86 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425207 | 1.00 | PIM1 (0.38) | PIM1PIM3PIM2NTMT1BCHE | |
| SCHEMBL1579124 | 0.83 | PIM1 (0.44) | PIM1PIM3PIM2DPP4KDM4E | |
| SCHEMBL2425209 | 0.78 | MAP4K4 (0.49) | PIM1PIM3PIM2DPP4L3MBTL1 | |
| SCHEMBL12283721 | 0.78 | MAP4K4 (0.49) | PIM1PIM3PIM2DPP4L3MBTL1 | |
| SCHEMBL12283785 | 0.73 | PIM1 (0.52) | PIM1PIM3PIM2L3MBTL1 | |
| SCHEMBL28777524 | 0.73 | CCNE1 (0.33) | — | |
| SCHEMBL27989183 | 0.72 | NTMT1 (0.50) | NTMT1KDM4EL3MBTL1 | |
| SCHEMBL29265663 | 0.70 | ACACB (0.43) | — | |
| SCHEMBL28232720 | 0.69 | PIM1 (0.41) | PIM1PIM3PIM2KDM4EATM | |
| SCHEMBL28613367 | 0.69 | ACACB (0.41) | PIM1PIM3PIM2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | PIM1 1/4885PIM3 2/4885PIM2 3/4885 |
| US-20150051185-A1 | Chemical Compounds 251 | PIM1, PIM3, PIM2 | PIM1 1/4885PIM3 2/4885PIM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.